£2.4M
The Cambridge-based biotechnology startup has closed a £2.4m round backed by investors from the UK and US.
S
Spirea
Spirea develops targeted antibody-drug conjugates designed to improve cancer treatment efficacy and safety.
£2.4MTotal raised
Spirea is a Cambridge-based biotechnology company developing antibody-drug conjugate treatments designed to target solid tumours.
Filed accounts
Net current assets
Members only
Total assets less current liabilities
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Current assets
Members only
Employees
Members only
Cash, assets and headcount from Spirea's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
MO
Myriam Ouberai
Chief Executive Officer
Myriam is the founder and chief scientific officer of Spirea. She previously served as the company's chief executive officer and spent seven years as a senior research associate at the University of Cambridge Nanoscience Centre.
LinkedIn
Adam Collier
Head of Business Operations
Adam brings business development and licensing experience in the biotechnology sector. He currently serves as Chief Business Officer at Spirea, following roles including Head of Business Development at Isogenica Limited.
LinkedInInvestors
Funding history
The seed round was led by Meltwind and Start Codon to accelerate in vivo proof-of-concept studies.